Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
28 Fevereiro 2024 - 6:01PM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company developing breakthrough treatments for
immune-mediated and oncologic disorders, today announced that Chris
Kirk, Co-founder and Chief Executive Officer, will participate on
the Cardiorenal Corporate Panel at the TD Cowen 44th Annual Health
Care Conference. The panel will be held on Tuesday, March 5, 2024,
at 10:30 a.m. ET.
A webcast of the panel discussion will be available on the
“Events & Presentations” section of the Company’s website at
www.kezarlifesciences.com. Following the event, an archived webcast
will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company developing novel treatments for immune-mediated and
oncologic disorders. Zetomipzomib, a selective immunoproteasome
inhibitor, is currently being evaluated in a Phase 2b clinical
trial for lupus nephritis and a Phase 2a clinical trial for
autoimmune hepatitis. This product candidate also has the potential
to address multiple chronic immune-mediated diseases. Kezar’s
oncology product candidate, KZR-261, targeting the Sec61 translocon
and protein secretion pathway, is being evaluated in an open-label
dose-escalation Phase 1 clinical trial to assess safety,
tolerability and preliminary tumor activity in solid tumors. For
more information, visit www.kezarlifesciences.com, and follow us on
LinkedIn, Facebook, Twitter and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228522659/en/
Investor and Media Contact: Gitanjali Jain Vice President,
Investor Relations and External Affairs Kezar Life Sciences, Inc.
gjain@kezarbio.com
Kezar Life Sciences (NASDAQ:KZR)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Kezar Life Sciences (NASDAQ:KZR)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024